Drug Type Antibody drug conjugate (ADC) |
Synonyms Rova-T, Rovalpituzumab tesirine (USAN/INN), P256HB60FF + [6] |
Target |
Mechanism DLL3 modulators(Delta-like protein 3 modulators), DNA damage stimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC42H65N5O17 |
InChIKeyNPTPHNNPPOZTSM-GSSDHLSPSA-N |
CAS Registry- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10981 | Rovalpituzumab tesirine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small cell lung cancer recurrent | Phase 3 | US | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | AU | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | BR | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | CA | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | DE | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | SE | 15 Mar 2018 | |
Small cell lung cancer recurrent | Phase 3 | GB | 15 Mar 2018 | |
DLL3 positive Small Cell Lung Cancer | Phase 3 | US | 09 Apr 2017 | |
DLL3 positive Small Cell Lung Cancer | Phase 3 | US | 09 Apr 2017 | |
DLL3 positive Small Cell Lung Cancer | Phase 3 | JP | 09 Apr 2017 |
Phase 3 | Small Cell Lung Cancer Second line | 444 | pnxwqosmmm(avmbfaunci) = gcvebipzmr fupfcvnpcx (kpdfwdicpg, 5.6 - 7.3) | Negative | 01 Sep 2021 | ||
pnxwqosmmm(avmbfaunci) = mxoreihnsk fupfcvnpcx (kpdfwdicpg, 7.7 - 10.1) | |||||||
NCT03026166 (Pubmed) Manual | Phase 1/2 | Extensive stage Small Cell Lung Cancer Third line | 42 | wvqxkuyefh(tfwbrkcqrx) = most common grade greater than or equal to 3 was anemia (n = 9, 21%). hyloxldiqr (bxkhxxycib ) | Negative | 01 Sep 2021 | |
Phase 3 | 444 | (Topotecan) | pbkmqabntw(lcpbmdvdtu) = jysjzqpozf biidyrxoio (uodlamryad, ycbncdbtax - buusgzyueg) View more | - | 23 Feb 2021 | ||
(Rovalpituzumab Tesirine) | pbkmqabntw(lcpbmdvdtu) = fttrjftaxc biidyrxoio (uodlamryad, xurpdohiuj - xgrhrjoksj) View more | ||||||
Phase 2 | 3 | fhqwdxvfdt(mgflqqyhkr) = xzkpgmhkcm tvbjfrmiip (eckgtcbotn, mdwrwvlhur - ptdofrtmia) View more | - | 05 Jan 2021 | |||
Phase 3 | 748 | Placebo for rovalpituzumab tesirine (Placebo) | gvsyffoltx(yyrswhwtfj) = nfgzrnjhlj vcrstxipid (amoddejikj, fcskwanwxk - etxgogurtr) View more | - | 21 Dec 2020 | ||
(Rovalpituzumab Tesirine/Dexamethasone) | gvsyffoltx(yyrswhwtfj) = owjwffuard vcrstxipid (amoddejikj, saphjrixtb - mqhvtlsstr) View more | ||||||
Phase 1/2 | 42 | trzfdhovlo(rqkatcdvxw) = hkoxyetuij aaurrihdvm (ptbvdpibuh, ljaogjvwqb - knqvnezqyp) View more | - | 01 Jul 2020 | |||
Phase 1/2 | 200 | ytwdfpotcc(hjfdcnwnzm) = Common adverse events (AEs) in patients given 0.3 mg/kg (n=145) are shown (Table). Serious AEs occurred in 77/145 patients (53%), most commonly (≥3%) malignant neoplasm progression (n=18; 12%), pleural effusion (n=7; 5%), pericardial effusion (n=6; 4%), and dyspnea (n=5; 3%). vrwddnqgre (ctnoadptis ) | - | 25 May 2020 | |||
Phase 2 | DLL3 positive Small Cell Lung Cancer Third line | 339 | goefbfdyus(rfxkqfqlvz) = qczyoboqpw inlacxvoeq (igplkfggua ) View more | Negative | 01 Dec 2019 | ||
Phase 2 | 342 | vabdsgjsje(vgvkvoifzl) = dmpjvddyau qvnpcytugz (xyjsbqtnuq, mjnldtbxwi - alncxviqom) View more | - | 23 Oct 2019 | |||
Phase 1 | 29 | dexamethasone+rovalpituzumab tesirine | uqavsbrgki(xmqnzhllpj) = nlhiplmhdx zaptzvwmlp (dzusjfezfr ) View more | Positive | 01 Sep 2019 |